1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 2: 
Average sensitivity and specificity for 2 readers and 53 sites of CVT in 39 patients assessed on venous segment level and on patient level
Imaging Technique, % (95% CI)Pair-wise Difference, P Valuea
T2WGRETOF MRVCombo-4D MRV
Venous segment levelb
All segments, all stages
    Sensitivity (n = 53)62 (48–74)49 (34–64)72 (59–81)76 (64–84)2(.002), 5(.006)
    Specificity (n = 181)98 (94–99)98 (94–99)96 (92–97)99 (96–100)3(.02)
Dural venous sinuses, all stages
    Sensitivity (n = 34)72 (55–84)39 (24–57)82 (66–92)97 (84–100)1(.003), 2(<.001), 3(.03), 4(.03), 5(<.001), 6(.005)
    Specificity (n = 122)99 (95–100)98 (94–99)95 (90–97)99 (95–100)3(.02), 4(.007)
Cortical veins, all stages
    Sensitivity (n = 19)45 (27–64)66 (46–81)53 (35–69)37 (20–58)2(.01)
    Specificity (n = 59)95 (86–99)97 (87–100)98 (89–100)99 (91–100)
All segments
    Sensitivity, acute stage (n = 16)56 (25–85)56 (36–74)75 (44–96)63 (44–76)N/A
    Sensitivity, subacute stage (n = 31)63 (48–75)50 (29–71)71 (57–80)84 (67–94)N/A
    Sensitivity, chronic stage (n = 6)75 (36–94)20 (6–61)67 (32–88)67 (30–90)N/A
Patient level, all stagesc
    Sensitivity (m = 20)75 (56–85)55 (38–71)83 (63–91)90 (69–97)2(<.001), 5(.002)
    Specificity (m = 19)97 (77–100)95 (74–100)79 (58–90)100 (80–100)3(.009), 4(.04)
  • Note:—n refers to the number of venous segments included in the calculation; m refers to the number of patients included in the calculation.
  • a Superscripts 1, 2, 3, 4, 5, and 6 indicate significant difference between combo-4D MRV and T2W, combo-4D MRV and GRE, combo-4D MRV and TOF MRV, TOF MRV and T2W, TOF MRV and GRE, and between GRE and T2W, respectively.
  • b Binary test on venous segment level, ie, test is positive if score is >3.
  • c Binary test on patient level, ie, test is positive for patient if score >3 for any of the patient's venous segments.